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Background: Studies into the regulation of interleukin-10 (IL-10), have focused only on the molecular or single-cell
level. The cues that induce IL-10 in the context of cell-to-cell communication are scarce. To fill this gap, this study
elucidates the cell-to-cell interaction dependent regulation of IL-10.
Results: The simultaneous activation of CD4+ T cells via CD3/CD28 and stimulation of macrophages via CpG and
their intercellular communication with each other in the same microenvironment is necessary to induce a
synergistic expression of IL-10. NF-κB1, ERK, and STAT3 are positive regulators of this cell-to-cell communication
mediated molecular change of IL-10 induction. Strikingly, the activation of CD40/CD154 signaling is a negative
regulator of IL-10 levels by CD3/CD28/CpG.
Conclusions: These findings are of prominence as CD3/CD28/CpG treatment can induce the anti-inflammatory
cytokines IL-10 and IL-30, and the activation or inhibition of the CD40/CD154 acts as molecular rheostat of the
expression of IL-10 or IL-30. More importantly, this not only serves as an example of IL-10 regulation at the cellular
via coordination of two signals from two cell types, but these findings also lay the molecular and cellular
groundwork for future studies to investigate how to manipulate IL-10 or IL-30 production during inflammation,
cancer, or autoimmune diseases.
Keywords: IL-10, IL27p28 (IL-30), NF-κB1, STAT3, CD40/CD154, CD4+ T cells, pERK, F4/80 cellsBackground
The immune response has evolved to clear pathogens and,
subsequently, to limit this immune response to protect
the host from damage, therefore, a successful response
must balance these pro- and anti-inflammatory signals.
Particularly, IL-10 is a major anti-inflammatory cytokine
that prevents autoimmune and inflammatory diseases [1,2].
Additionally, IL-10 has been shown to be a feedback regula-
tor of Th1, Th2, and allergenic immune responses [3,4].
This cytokine is produced by different immune cell types,
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reproduction in any medium, provided the ordendritic cells (DC), and several T cell subsets (including
Th1, Th17, Foxp3+ Tregs, and regulatory type 1 cells Tr1)
[5-8]. The production of IL-10 from CD4+ T cells, CD8+
T cells, and myeloid cells (e.g., DC) have all been shown to
play important roles in regulating immunopathology in
different infectious disease.
Different cues within the microenvironment regulate
the IL-10 expression in a cell-specific manner. This obser-
vation is of importance as IL-10 expression by different
cells, namely effector CD4+ or regulatory T (Treg) cells, can
have different roles in the same infection. For example, in
L. major infections IL-10 from effector Th1 cells is neces-
sary for suppression of inflammatory responses during
acute infection, whereas IL-10- producing antigen-specific
Foxp3+ CD4+ T cells (T regs) suppress the clearance of the
parasite by the effector CD4+ T cells [9,10]. Additionally,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fers among cell types. For example, in Th1 cells, MAF and
SMAD4 are key IL-10 transcription factors; however, in
Th2 cells, GATA3, Jun, and MAF are specific transcription
factors for IL-10 expression, while STAT3 or STAT1 are
the important factors for IL10 in Th17 expression [11-14].
While most of the regulation of IL-10 expression de-
scribed in the literature is limited to the molecular and
single cell level within a specific type of immune cell,
the cell-to-cell interaction-dependent regulation has not
been examined. Understanding the cell-to-cell communica-
tion in regulating IL-10 levels is important, as it not only
replicates the inter-cellular communication that occurs
in vivo, but also integrates different cues within the micro-
environment to account for IL-10 levels globally. Obtaining
this information can lead to more effective interventions
during inflammatory and pathogenic immunopathologies.
Here we demonstrate that simultaneous activation of two
types of cells, CD4+ T cells via CD3/CD28 and CpG-
stimulated macrophages and their interaction in the same
microenvironment is crucial to induce robust expression of
IL-10. Furthermore, this upregulation of IL-10 occurs via
NF-κB1 and STAT3 activation. This work is of importance
as it provides an example of IL-10 regulation at the cell-to-
cell and molecular level via coordination of two signals
from two cell types.
Results
The essential transcription factor(s) or pathway(s) that
activates IL-10 expression is dependent on the type of
both the cell and stimuli [11,15]. While many studies
have attempted to understand the regulation of IL-10 in
a specific cell type through a specific stimulus, the role of
cell-to-cell communication or interaction in the induction
of IL-10 is largely unknown. To test the coordination of dif-
ferent types of immune cells in inducing IL-10, two signals
that stimulate different cell types were independently or
simultaneously applied to the cell mixtures (splenocytes).
The first signal, comprised of CD3 and CD28 (CD3/CD28),
mimics the first and second signals that activate T cells and
can induce moderate amounts of IL-10. The other stimula-
tion signal was CpG which activates cells via the TLR9
receptor present on many types of cells but primarily on
antigen presenting cells (APCs) such as macrophages, DC,
and B cells, and can induce IL-10 expression as well. The
rationale for using splenocytes was that this cell mixture
represents a variety of immune cells, and additive or
synergistic effects of different stimuli can be observed.
Additionally, these two sets of signals, CD3/CD28 plus
CpG (CD3/CD28/CpG), synergistically induces high levels
of the anti-inflammatory cytokine IL-30 [16], therefore
suggesting that the same phenomenon may occur in IL-10
regulation. Indeed, the treatment of cells with the CD3/
CD28/CpG combination induced synergistic expression ofIL-10 in splenocytes; however, treatment of cells with ei-
ther CD3/CD28 or CpG alone induced a relatively small
increase in IL-10 production (Figure 1A). Kinetic studies
showed that the highest induction of IL-10 via CD3/
CD28/CpG occurs 72 hours after treatment (Figure 1B).
CD3/CD28/CpG induced significantly higher IL-10 levels
compared to either signal alone, whereas treatment with
CD3/CD28 and control isogenic CpG (in which CpG was
switched to GpC) did not effectively raise IL-10 levels
(Figure 1C). High levels of IL10 levels were not due in-
crease in cell proliferation by the combination treatment
(Additional file 1: Figure S1). These data revealed that
either CD3/CD28 or CpG alone induces a moderate
amount of IL-10 expression, and the combination of
these two treatments synergistically raises IL-10 levels.
This result suggests that simultaneous activation of both
T cells and TLR9+ cell signaling is crucial for inducing
robust IL-10 expression.
To determine whether both primary and secondary
signals are required to coordinate with CpG to boost IL-
10 expression, splenocytes were activated in the presence
of CpG with agonist antibodies for the T cell activators
CD28, CD3, or both CD3 plus CD28. Interestingly, efficient
activation of T cells with both the primary (CD3) and sec-
ondary signals (CD28) and not with either signal alone is
able to induce high levels of IL-10 production (Figure 1D).
To determine whether this effect is specific for TLR9, vari-
ous TLR ligands were used in the presence of CD3/CD28
antibodies. The enhanced expression of IL-10 in coordin-
ation with T cell activation is not specific only to TLR9
since stimulation with other TLR ligands induced expres-
sion of IL-10 (Figure 1E). This observation suggests that
many different stimuli from pathogens to APCs in the
presence of activated T cells induce high levels of IL-10,
confirming that many activation pathways converge at
IL-10 to protect the host against inflammation.
Immunocompromised nude mice were used to further
confirm the role of T cells, and the requirement of T and
other immune cell interaction in inducing high levels of
IL-10. As predicted, the absence of functional T cells elimi-
nated the CD3/CD28/CpG-mediated synergistic induction
of IL-10 (Figure 2A). Similar results were also seen in im-
munodeficient SCID mice (Figure 2B). Furthermore, deple-
tion of CD4 cells, but not CD8, DC, or B cells, inhibited
the most IL-10 expression (Figure 2C), suggesting that
CD4+ T cell activation via CD3/CD28 is essential for
maximal induction of IL-10.
The initial hypothesis was that interaction of two differ-
ent types of immune cells via the CD3/CD28/CpG signal
is needed to maximally upregulate IL-10. From the deple-
tion studies, we saw that CD4+ T cells play a crucial role.
Amongst the antigen presenting cells tested, depletion of
DC and B cells did not significantly lower IL-10, suggest-
ing that macrophages might be the key interacting cells.
Figure 1 Coadministration of CD3/CD28 and CpG induce robust amounts of IL-10 expression in splenocytes when compared to either
signal alone. (A) Splenocytes were treated with CpG, CD3/CD28, CD3/CD28/CpG, or left untreated for 72 hours and analyzed for IL0 production
by ELISA. (B) Splenocytes were treated with CD3/CD28/CpG for 0, 48, or 72 hours, and IL-10 levels were measured by ELISA. (C) Supernatants of
splenocytes treated with either CpG or control ODN (ctrl CpG) in the absence or presence of CD3/CD28 for 72 hours were analyzed for IL-10
production by ELISA. (D) Splenocytes were treated with CpG in the presence or absence of various T cell-activating antibodies (CD28, CD3, or
CD3/CD28) for 72 hours, and IL-10 expression in the supernatants was measured via ELISA. (E) Supernatants from splenocytes treated as indicated
for 72 hours were analyzed for IL-10 production by ELISA. *, P <0.05. N = 3.
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mixture studies using different antigen presenting cells.
The purified CD4+ T cells were co-incubated with various
types of APC, such as B cells, macrophages, and DC and
the resulting supernatants were tested for IL-10 expression.
We found that a mixture of macrophages and CD4+ T
cells yields a high level of IL-10 expression upon ex-
posure to CD3/CD28/CpG (Figure 2D), whilst B cells
and DC only play a minor role in the induction of IL-
10. These results clearly indicate that the interaction
between CD4+ T cells and macrophages are required to
induce a high level of IL-10 expression in the presence
of this combination of signals.
To confirm that CD4+ T cells and macrophages interact
to induce high levels of IL-10 expression, macrophages
were reconstituted with CD4+ T cells, CD4+ T and NK
cells, or whole T cells (CD3+ cells). As expected, reconsti-
tution of macrophages with CD4+ T cells raised the IL-10
levels following CD3/CD28/CpG treatment (Figure 2E).
Additionally, NK cells boosted the level of CD3/CD28/
CpG-induced IL-10 expression, yet the overall expressionlevels were much lower when compared to those of CD4+
T cells. These differences suggest that CD4+ T cells play
the major role in IL-10 biology.
T cells can activate macrophages via cell contact. To
determine whether macrophages and T cells need physical
contact to induce IL10 upregulation, macrophages and
CD4+ T cells were coincubated in the presence or absence
of a transwell barrier, treated with CD3/CD28/CpG, and
analyzed for IL10 protein expression. In the presence
of a barrier, CD3/CD28/CpG failed to induce any IL10
expression, suggesting that the expression of IL10 re-
quires direct cell-to-cell contact between macrophages
and CD4+ T cells (Figure 2F) suggesting that cell-cell
communication is needed to upregulate IL10.
While the data above suggests that interaction between
both macrophages and T cells is needed to effectively pro-
duce IL-10, the cell source that produces IL-10 via the
combination treatment is not known. To understand this
origin of IL-10, splenocytes were treated with CD3/CD28,
CpG, or the combination treatment, and these cells were
stained via flow cytometry for IL-10 expression either in
Figure 2 Coordination between T cells and macrophages induces the highest expression of IL-10 in a cell-contact dependent manner.
(A, B) Supernatants from wild type and nude (A, Balb/c background) or wild type and SCID (B, C3H background) splenocytes were treated with
CD3/CD28/CpG for 72 hours and then analyzed for IL-10 production by ELISA. (C) Non-depleted splenocytes or the ones depleted for CD3, CD4,
CD8, DC, and NK cells were treated with CD3/CD28/CpG for 72 hours, and the supernatants were analyzed for IL-10 expression via ELISA. (D)
Purified splenic B cells, DC, CD4+ T cells, or peritoneal macrophages were coincubated in the presence or absence of purified CD4+ T cells, treated
with CD3/CD28/CpG for 72 hours and analyzed for IL-10 expression in the supernatants by ELISA. (E) Peritoneal macrophages were coincubated
in the presence or absence of purified NK, whole T (CD3+ T), CD4+ T, or a combination of CD4+ T and NK cells; treated with CD3/CD28/CpG for
72 hours; and analyzed for IL-10 expression in the supernatants via ELISA. (F) Peritoneal macrophages were coincubated with purified CD4+ cells
in the presence or absence of a transwell barrier, treated with CD3/CD28/CpG for 72 hours, and analyzed for IL-10 expression in the supernatant
via ELISA. *, P <0.05. N = 3.
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antibody F4/80) (Figure 3A). Interestingly, the combination
treatment induces a higher number of macrophages
(Figure 3C), while it has no effect on the percentage of
CD4+ T cells (Figure 3B). Meanwhile, the CD3/CD28/CpG
combination treatment significantly increases IL10 ex-
pression in CD4 cells (Figure 3D), while it induces only
a modest increase of IL10 in macrophages (Figure 3E).
Aside from inducing higher levels of IL10 per cell in the
CD4 cell population, the combination treatment CD3/
CD28/CpG additionally results in a reduction of Treg
cells in vitro (Additional file 2: Figure S2).
Therefore, this data suggests that both CD4+ T cells and
macrophages contribute to increased IL-10 expression.
While it is understood the T and macrophage coordin-
ation needed to induce IL-10, the transcription factors
involved in driving IL-10 expression by the cell-to-cell
communication has not been investigated. Activation of
transcription factors NF-κB1 and STAT3 play a crucial
role in regulation of IL-10 in a single cell system [17,18].
Importantly, NF-κB1 has been shown to transactivate the
promoter of IL-10. To determine whether CD3/CD28/CpG
induces IL-10 through modulation of NF-κB1, splenocytes
were treated with CD3/CD28/CpG in the presence or ab-
sence of NF-κB inhibitor (Figure 4A). The presence of the
NF-κB inhibitor significantly inhibited IL-10 expression.To further prove that the absence of NF-κB indeed affects
IL-10 expression, splenocytes defective in the NF-κB
pathway (NF-κB1−/− splenocytes) were treated with the
combination treatment. Indeed, the absence of NF-κB1
hinders IL-10 expression by CD3/CD28/CpG by 8 fold
(Figure 4B). Indeed, since both NF-κB1 activation and
the cell communication plays a major role in regulating
IL-10 expression, it is important to understand whether
NF-κB1 signaling primarily in macrophages or T cells
is needed. Interesting, the absence of NF-κB1 in mac-
rophages plays a major role in IL-10 regulation, but the
absence of NF-κB1 signaling in T cells only plays a minor
role (Figure 4C).
Since it is known that NF-κB1 is the crucial transcription
factor to induce IL10 in macrophages, we sought to deter-
mine the molecular mechanism that was activated in CD4+
T cells. Both pERK and pSTAT3 were upregulated in
CD4+ T cells by the combination treatment CD3/CD28/
CpG when compared to untreated samples (Figure 4D, E)
at 72 hours. Meanwhile, CD3/CD28/CpG and CD3/CD28
exert the same effect on T cells, and induce similar levels
of either pSTAT3 or pERK (Figure 4D). Time course study
showed that pERK was induced at a similar trend at 10,
30 min, and 1 hour as it was at 72 hours (Additional file 3:
Figure S3). To verify that indeed these two transcription
factors are involved IL10 induction by CD3/CD28/CpG,
Figure 3 CD3/28/CpG induces IL-10 production in both macrophages and CD4+ T cells. (A) Diagram of FACS analysis. (B, C) Splenocytes
left untreated or treated with CpG, CD3/CD28, CD3/CD28/CpG for 72 hours and number of CD4 (B) or F4/80 (C) were measured via FACS.
(C, D) Median fluorescence intensity of IL10 in the CD4+ (D) or F4/80+ (E) gated cells. *, P <0.05. N = 3.
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Indeed, ERK or STAT3 inhibition significantly affects
IL-10 levels in a dose-dependent manner respectively
(Figure 4F, G). Furthermore, inhibition of both NF-κB1
and STAT3 (50 μM) pathways obstructs IL-10 expression
to almost undetectable levels (Figure 4H).
The fact that both IL-10 and IL-30 are induced via the
CD3/CD28/CpG provokes the question of whether the
combination treatment can preferentially induce one cyto-
kine over the other under different contextual clues. If so,
which pathway is involved in this process? CD154 is one of
the ligands on the Tcell membrane that can bind to and ac-
tivate the CD40 receptor on macrophage. Additionally, this
pathway is critical to raise IL-30 expression when combined
with CD3/CD28/CpG [16]. To evaluate the involvement of
CD40/CD154 pathway during CD3/CD28/CpG-mediatedregulation of IL-10, we compared IL-10 levels induced
by CD3/CD28/CpG in wild type, CD40−/−, and CD154−/−
splenocytes (Figure 5A and Figure 5B). Opposite to IL30
induction by CD3/CD28/CpG, the absence of CD40 or
CD154 raised IL-10 expression by more than 2 fold
compared to wild type, indicating that the CD40/CD154
pathway is a negative rather than positive regulator. Fur-
thermore, wild type splenocytes treated with agonist CD40
antibody (anti-CD40) lowered the IL-10 production by one
half (Figure 5C). These results confirm the data from the
CD40−/− and CD154−/− knockout splenocytes. Meanwhile,
agonist anti-CD40 antibody in the presence of the CD3/
CD28/CpG treatment significantly raises IL-30 levels by at
least two fold (Figure 5D). To exclude the possibility that
the observed effects are specific to the time point chosen,
we tested different time points. Indeed, this data showed
Figure 4 CD3/CD28/CpG regulates IL-10 via activation of NF-κB1,pERK, and STAT3. (A) Splenocytes were treated as indicated for 72 hours and
IL-10 levels were measured by ELISA. (B) Supernatants from wild type or NF-κB1−/− splenocytes treated with CD3/CD28, CpG, or TX (CD3/CD28/CpG)
for 72 hours were analyzed for IL-10 production by ELISA. (C) Peritoneal macrophages from wild type or NF-κB1−/− mice were coincubated with
purified CD4+ T cells from either wild type or NF-κB1−/− mice, treated with CD3/CD28/CpG for 72 hours and the supernatants were measured for IL-10
expression by ELISA. (D) Splenocytes treated with CD3/CD28, CpG, or TX (CD3/CD28/CpG) for 72 hours were stained for CD4 and pERK or CD4
and pSTAT3. Histograms show pERK or pSTAT3 levels from gated T cells. (E) Quantification of median fluorescence intensity of pERK levels in
CD4 cells (N = 3). (F) Splenocytes were treated with ERK inhibitor U0126 at various doses for 72 hours in presence of CD3/CD28/CpG, and IL-10
levels were measure by ELISA. (G) Splenocytes were treated with STAT3 inhibitor NSC 74859 at various doses for 72 hours in presence of CD3/
CD28/CpG, and IL-10 levels were measure by ELISA. (H) Wild type or NF-κB1−/− splenocytes in presence or absence of STAT3 inhibitor
(STAT3i, 50 μM) were treated with CD3/CD28/CpG for 72 hours and analyzed for IL-10 production by ELISA. *, P <0.05. N = 3.
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duced IL10 and increased IL30 in all the tested time points
(Figure 5E, F), therefore suggesting that activation of CD40
during the combination treatment acts as a molecular rheo-
stat in the regulation of IL10 and IL30 [16].Our previous study shows that CD3/CD28/CpG in-
duces IL-30, and this study shows that the same stimuli
induce IL10 expression [16]. An intriguing question is
whether IL-10 regulates IL30 via the CD3/CD28/CpG
combination. To answer this question, splenocytes were
Figure 5 Activation or inhibition of CD40/CD154 pathway in the presence of CD3/CD28/CpG acts as a switch in the expression of IL-10
or IL-30. (A) Supernatants from wildtype or CD40−/−splenocytes were treated with CD3/CD28/CpG for 72 hours were analyzed for IL-10 production
by ELISA. (B) Supernatants from wild type or CD154−/− splenocytes treated with CD3/CD28/CpG for 72 hours were analyzed for IL-10 production by
ELISA. (C, D) Splenocytes from wild type mice were treated with the indicated treatments in the presence of control or anti-CD40 antibodies for
72 hours, and IL-10 (C) or IL-30 (D) expression was measured in the supernatants using ELISA. (E, F) Splenocytes from wild type mice were treated with
the indicated treatments in the presence of control or anti-CD40 antibodies for 24, 48, or 72 hours, and IL-10 (E) or IL-30 (F) expression was measured
in the supernatants using ELISA. *, P <0.05. N = 3.
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absence of IL-10. In the presence of recombinant IL-10,
IL-30 expression levels induced by CD3/CD28/CpG were
significantly inhibited (Figure 6A), suggesting that IL-10
negatively regulates IL-30 expression. Additionally, in
IL-10−/− splenocytes, CD3/CD28/CpG induces higher
levels of IL-30 when compared to wildtype counterparts
(Figure 6B). These data suggest that the combination
treatment induces high levels of both IL-10 and IL-30,
but IL-10 also serves as a negative inhibitor of IL-30.
However, recombinant IL30 boosts IL10 levels in a dose-
dependent manner (Figure 6C).
Ligation of CD40 (via the agonist antibody) inhibits
IL-10 upregulation by CD3/CD28/CpG (Figure 4), while
it promotes IL-30 expression [16]. This observation pro-
vokes the question whether IL-10 or activation of CD40
signaling depend on each other to alter IL-30 expression.
Indeed, even in the presence or absence of IL-10, anti-
CD40 stimulation upregulates IL-30 expression (Figure 6D).
These results suggest that both IL-10 and CD40 can regu-
late IL-30 expression via two separate mechanisms.The activation of the CD40 pathway via the agonist
antibody lowers IL-10 induction while the activation of
NF-κB1 and STAT3 raises IL-10 expression. One possibility
is that the activation of CD40 lowers NF-κB1 or STAT3 ac-
tivation over time, therefore affecting IL-10 expression. To
test this hypothesis, splenocytes were treated in the absence
or presence of agonist anti-CD40 antibody over time and
probed for the phosphor-STAT3 or NF-κB1 p65, or NF-κB
p50/105. There was no difference in the levels of STAT3
activation or the total levels of NF-κB p50/105 by the
engagement of CD40 in splenocytes (Figure 6E). We also
tested whether these specific transcription factors were
upregulated in specific cell populations, such as CD4+ T
cell or macrophages. Indeed, no differences in the levels of
p-p65 or pSTAT3 were observed between samples treated
with CD3/CD28/CpG in either the presence or absence of
CD40 (Figure 6F). Additionally, even in absence of NF-κB1
signaling, anti-CD40 can further inhibit IL-10 expression
levels (Figure 6G). Because IL10 and IL30 also regulate each
other and CD40/CD154 acts a rheostat in the regulation
of IL10 or IL30, one possibility is that these cytokines
Figure 6 Regulation of IL-10 and IL-30 via activation of CD40 signaling. (A) Supernatants from splenocytes treated with CpG, CD3/CD28, TX
(CD3/CD28/CpG), in the presence or absence of rIL-10 for 72 hours were analyzed for IL-30 production by ELISA. (B) Wild type or IL-10−/− splenocytes
were treated as indicated for 72 hours, and IL-30 levels were measured by ELISA. (C) Splenocytes were treated with CD3/CD28/CpG in the presence of
recombinant IL30 at 50 and 100 ng/ml for 72 hours, and IL-10 levels were measured by ELISA. (D) Wild type or IL-10−/− splenocytes were treated with
CD3/CD28/CpG for 72 hours in the presence of control or anti-CD40 antibodies, and IL-30 levels were measured by ELISA. (E) Harvested pellets of
splenocytes treated with anti-CD40 or control antibody for the indicated time points were probed for pSTAT3, p-p65, p50/105, and actin.
(F) Splenocytes were treated with CD3/CD28/CpG in the presence or absence of anti-CD40 activating antibody and the levels of p-p65 and
p-STAT3 in the CD4+ T cells or macrophages were measured via flow cytometry. (G) Supernatants from wild type or NF-κB1−/− splenocytes
treated with CpG, CD3/CD28, TX (CD3/CD28/CpG), or CD3/CD28/CpG in the presence of activating anti-CD40 for 72 hours were analyzed for
IL-30 production by ELISA. *, P <0.05. N = 3.
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splenocytes were treated with rIL10 or rIL30 and the
levels of CD154 in CD4+ T cells and CD40 levels on
macrophages were tested. Neither rIL0 nor rIL30 altered
CD40 or CD154 in macrophages or T cells, respectively
(Additional file 4: Figure S4). Overall, these data dem-
onstrate that CD40, NF-κB1, and STAT3 pathway can
regulate IL-10 independently of each other.
Discussion
Owing to the vital role of IL-10 in the immune response
and the link between defective IL-10 production and
certain autoimmune and inflammatory diseases as well
as cancer, an understanding of the molecular and cellu-
lar mechanisms that regulate this cytokine is critical
[1,2]. Extensive studies have investigated the regulationof IL-10 within single immune cell subsets and shown
that IL-10 regulates its own expression through posi-
tive and negative feedback loops; however, the cell-to-
cell interaction dependent regulation of IL-10 within
diverse immune cell populations is largely unknown.
In this study we discovered that cell-to-cell commu-
nication via the two signaling pathways CD3/28 and
CpG in CD4+ T cells and macrophages, respectively,
is the key to effectively induce IL-10 expression. We
further delved into the mechanism, and we discovered
that NF-κB1 and STAT3 are positive regulators, while
CD40/CD154 signaling is a negative regulator of IL-10 ex-
pression via the combination treatment CD3/CD28/CpG
(Figures 4 and 5).
The activation or inhibition of the CD40/CD154 sig-
naling pathway acts as a switch to determines whether
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IL-30. The activation of this pathway is a negative regulator
of IL-10 in the presence of the combination treatment
CD3/CD28/CpG. Three lines of evidence confirm that
CD40/CD154 plays a negative role in the regulation of
IL-10 in this study (Figure 5). First, the absence of CD40 in-
creases IL-10 CD3/CD28/CpG-induced expression levels.
Second, the effect on the expression of IL-10 by the ab-
sence of CD154 mirrors the data seen in CD40−/− spleno-
cytes and shows that absence of this pathway promotes
IL-10 production. Third, the ligation of CD40 via the
agonist CD40 antibody also inhibits IL-10 expression
levels. Interestingly, the activation of CD40 can inhibit
IL-10 even in the absence of NF-κB1 which highlights
the complexity of IL-10 regulation in these models. The
role of CD40 in modulating IL-10 expression in the pres-
ence of the CD3/CD28/CpG (lowers IL-10 levels) is differ-
ent from simply activating CD40 directly on macrophages
without any other signals (raises IL-10 levels) [19]. These
findings are of interest as they display that the same
pathway under different circumstances can have a different
outcome in the regulation of IL-10. Additionally, the acti-
vation of CD40/C154 in the presence of CD3/CD28/CpG
differently regulates IL-30, in which case CD40 ligation
actually raises the levels of IL-30 [16]. The implications of
these findings are of importance because the cell-to-cell
communication via the CD3/CD28/CpG treatment can
induce both anti-inflammatory cytokines IL-10 and IL-30
and the activation or inhibition of the CD40/CD154 path-
way with CD3/CD28/CpG acts as a switch to determine
whether IL-10 or IL-30 is induced.
Here we discovered that NF-κB1 is a crucial factor that
integrates the CD3/CD28/CpG stimuli to induce IL-10
by the combination treatment. Likewise, it is the NF-κB1
activation within the macrophages that is primarily needed
to effectively induce IL-10 as evidenced by the fact that
a lack of NF-κB1 in macrophages but not in T cells sig-
nificantly hampers IL-10 induction. The involvement
of NF-κB1 in the model employed in these studies is in
concert with another study showing that NF-κB1 binds
to the proximal IL-10 promoter in mouse macrophages
upon LPS stimulation [17]. In addition to NF-κB1, the
activation of STAT3 also upregulates the IL-10 expression
via CD3/CD28/CpG. Furthermore, the inhibition of both
STAT3 activation and NF-κB1can further inhibit IL-10
expression to almost undetectable levels, which suggests
that STAT3 and NF-κB1 can act independently in regulat-
ing IL-10 (Figure 5). Additionally, this data also suggest
that these two transcription factors are the crucial ones to
regulate IL-10 via the cell-to-cell mediated communica-
tion. In summary, NF-κB1, STAT3 and CD40 are import-
ant regulators of IL-10 and can raise/lower IL-10 even in
the absence of each other, which suggests that the expres-
sion of IL-10 is complex and tightly regulated.Many differences are seen in the activated pathways
that lead to expression of IL-10 or IL-30 through CD3/
CD28/CpG combination treatment. For instance, the
activation of T cells in the presence of CpG is the only
signal necessary to induce IL-30, but IL-10 can be induced
by bacterial or protozoan remnants in coordination with
activated T cells. This difference suggests that IL-10 has
wider applications to attenuate an immune response
whilst IL-30 is only specific to bacterial wall remnants.
Interestingly, IL-10 might regulate IL-30 expression since
both these anti-inflammatory cytokines are induced by the
combination treatment. Indeed, IL-10 lowers IL-30 ex-
pression during the combination treatment CD3/CD28/
CpG, as the recombinant IL-10 and the knockout data
reveal the same conclusion (Figure 6A, B). These data is
of interest as it suggests that this treatment modality in-
duces two different anti-inflammatory cells, IL-10 and
IL-30, and at the same time, IL-10 acts as a negative
regulator of IL-30, thereby having a “build-in” negative
signal. Another explanation could be IL-10 does not
regulate IL-30 expression directly but probably indirectly
by inhibiting T cell proliferation: IL-10−/− splenocytes pro-
liferate more than the wildtype counterpart, and, hence,
produce more positive signal to induce IL-30 expression.
So, more experiments are needed to determine whether
IL-10 affects IL-30 directly or indirectly.
Conclusion
In conclusion, we have described a novel cellular mech-
anism that controls IL-10 production. Data presented
here reveal that coordination between an innate immune
cell-derived signal and a helper T cell-derived signal is ne-
cessary to induce a high level of IL-10 expression via the ac-
tivation of NF-κB1 and STAT3. Additionally, the activation
or inhibition of the CD40/CD154 signaling pathway acts as
a molecular rheostat to determines whether the CD3/
CD28/CpG treatments upregulate IL-10 or IL-30 These
findings lay the groundwork for future studies to investigate
how to differentially manipulate IL-10 or IL-30 production
during inflammation, cancer, or autoimmune diseases.
Materials and methods
Reagents
Vendors for all reagents were as follows: thiol-modified
CpG oligodeoxynucleotide (ODN) 1668 or control ODN
(Sigma), anti-mouse CD3 (eBioscience), anti-mouse CD28
(Biolegend), activating anti-CD40 (Novus, NBP1-06657), re-
combinant mouse IL12, IFNγ, and IL-10 (eBioscience), LPS
(Sigma), lipoteichoic acid (Invivogen), poly I:C (Invivogen),
concanamycin A (Sigma), and rat IgG (eBioscience), QNZ
(Cayman Chemicals), U0126 (Sigma Aldrich), and NSC
74859 (SelleckBio), pSTAT3, p-p65, STAT3 (Cell signaling),
pERK (Santa Cruz), CD154, FOXP3 (eBioscience), recom-
binant IL27p28 (IL30, Genscript).
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http://www.biosignaling.com/content/11/1/95Cell separation and coincubations
Splenocytes were prepared as previously described [20].
Purification of DC, B cells, natural killer (NK) cells, and
CD4+ T cells from splenocytes was performed using mag-
netic beads according to the manufacturer’s instructions
(StemSep). Peritoneal exudate macrophages were obtained
three days after intraperitoneal injection of 3% sodium
thioglycolate medium (2 mL per mouse, Sigma). Cells
were seeded into 24 well plates, and after 3 hours, the
cells were washed and fresh RPMI medium was added.
5 × 105 splenocytes were seeded in 0.75 ml of heat-
inactivated RPMI media, activated with CD3 (2.0 μg/mL)
and CD28 (0.5 μg/mL) (CD3/CD28) in the presence or
absence of CpG ODN 1668 (1 μg/mL) (CPG) for 72 hours
and the IL-10 or IL-30 levels in the supernatant were mea-
sured via IL27p28 or IL-10 ELISA) (R&D Systems and
eBioscience, respectively). When appropriate, splenocytes
were treated with anti-CD40 (10 μg/mL), LPS (1 μg/mL
on day 0 and 2), Poly I:C (50 μg/mL), lipoteichoic acid
(LTA, 5 μg/mL), rIL12 (50 ng/mL), IFNγ (50 ng/mL), IL-10
(20 ng/mL). Splenocytes depleted of various cell subsets
were seeded as mentioned above. For the coincuba-
tion assay of CD4 T cells, B cells, DC, whole T cells
(CD3+), NK cells, and macrophages, 4 × 105 cells of each
type were seeded in 500 μL of heat-inactivated RPMI
for 72 hours.Mice
CD40−/−, CD154−/−, NF-κB1−/−, and IL-10−/− mice were
obtained from Jackson Laboratories. C57Bl/6, nude, and
SCID mice where purchased from Harlan Laboratories. All
experiments were performed using 6–10 week old mice.
All the procedures on mice were approved by the IACUC
Committee at MD Anderson Cancer Center.Flow cytometry analysis
Splenocytes were treated as indicated in the figure, and
72 hours post-incubation, IL-10 expression was analyzed
via flow cytometry. Briefly, 4 hours prior to staining, cells
were incubated with Brefeldin A. Afterwards, cells were
washed in PBS, and stained for CD4 (1:100) or F4/80 (1:100
for 30′ 4°C. After incubation, the cells were permeabilized
for 20′ at 4°C, and blocked for FcRs via incubation with
anti-CD16 (5 μg/mL) for 20′ at 4°C. After blocking, cells
were stained with anti-pERK (1:200), anti- pSTAT3 (1:500),
anti-p-p65 (1:1000), or anti-IL-10-Pe antibody for 30′ at
4°C. At last, the cells were washed and analyzed by flow
cytometry using Attune (Invitrogen).Statistical analysis
Unpaired student’s T test was used to determine signifi-
cance among groups.Additional files
Additional file 1: Figure S1. The combination treatment does not
affect the splenocytes proliferation when compared to either treatment
alone. Splenocytes treated with CD3/CD28, CpG, or CD3/CD28/CpG for
72 hours and the number of viable cells were measured via trypan blue
exclusion.
Additional file 2: Figure S2. The combination treatment CD3/CD28/
CpG results in a reduction of Treg cells in vitro. Splenocytes treated with
CD3/CD28, CpG, or CD3/CD28/CpG for 72 hours and cells were stained
for CD4 and FOXP3.
Additional file 3: Figure S3. CD3/CD28 and CD3/CD28/CpG induce
ERK activation in CD4+ T cells. Splenocytes treated with CD3/CD28, CpG,
or CD3/CD28/CpG for 10, 30 minutes, or 1 hour. Cells were stained for
CD4 and pERK, and the median fluorescence intensity of activated pERK
was measured in the gated CD4 positive cells.
Additional file 4: Figure S4. IL10 or IL30 have no effect on CD40/
CD154 pathway. Splenocytes treated with CD3/CD28/CpG in the
presence or absence of recombinant IL10 or IL30. Cells were stained for
CD40 and F4/80 or CD154 and CD4. The median fluorescence intensity of
CD154 or CD40 was measured in CD4 or F4/80 gated cells, respectively.
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